Backed by Sinopharm Capital previously, Virogin Biotech will invest the series C proceeds in its clinical drug programmes and securing industry partnerships.

Precision cancer drug developer Novellus boosted its funding total to $75.5m with a round featuring SR One and Novartis Venture Fund.

The Kunlun-backed customer engagement software provider has closed its series C round at about $44m, having raised a similar amount in series C1 funding four months ago.

The testing services provider hiked its overall funding to more than $68m in a round backed by Alibaba Hong Kong Entrepreneurs Fund.

Novo Ventures and Sanofi Ventures co-led a series C round for the cancer therapy developer, which builds on work at Amsterdam UMC.

Novo Ventures and Sanofi Ventures co-led a series C round for the cancer therapy developer with backing from returning investor MRL Ventures Fund.

GV participated in a round that increased the on-demand healthcare service's overall funding to $107m, with the cash to go to expanding its operations.

Bonnier contributed to the $170m first close of a the urban farming technology developer's series C round, taking its debt and equity financing to at least $305m.